You are here

Novel cell-based Restorative Approach in Treatment of Diabetes-related Retinopath

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43EY023463-01A1
Agency Tracking Number: R43EY023463
Amount: $215,739.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NEI
Solicitation Number: PA13-088
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
*(FY14 USE 10008420)
CARLSBAD, CA 92011-4402
United States
DUNS: 617462234
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (760) 434-8646
Business Contact
Phone: (760) 434-8646
Research Institution

DESCRIPTION (provided by applicant): Retinal vascular diseases remain a common cause of vision loss and blindness with diabetes as the most common condition leading to retinopathy in adults in Western society. In particular, with type 1 diabetes the majority of patients will develo diabetic retinopathy (DR) with about 20-30% becoming legally blind while in type 2 diabetes more than 60% of patients will exhibit DR. With the well-documented global epidemic of type 2 diabetes, DR is likely to increase in incidence and prevalence since over 360 million people world-wide are projected to suffer from diabetes by 2030. Although therapies such as anti-VEGF agents and laser are currently available to treat macular edema and neovascularization, there is no treatment that regenerates damaged retinal vasculature with reestablishment of critical levels of blood flow needed to support and sustain recovery. Research over the last decade has shown that peripheral blood (PB)-derived CD34+ stem/progenitor cells are capable

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government